FY2029 Earnings Estimate for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – Equities research analysts at HC Wainwright decreased their FY2029 earnings per share estimates for shares of IN8bio in a research report issued to clients and investors on Friday, March 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.15 per share for the year, down from their prior estimate of $0.25. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s FY2030 earnings at $0.59 EPS.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08).

Several other equities research analysts have also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, January 22nd. Zacks Research raised shares of IN8bio to a “hold” rating in a research note on Thursday, January 15th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.00.

IN8bio Stock Performance

Shares of IN8bio stock opened at $1.89 on Monday. The business’s 50 day simple moving average is $2.00 and its 200 day simple moving average is $1.98. IN8bio has a 52-week low of $1.17 and a 52-week high of $7.50. The firm has a market cap of $18.47 million, a PE ratio of -0.42 and a beta of 0.01.

Hedge Funds Weigh In On IN8bio

A number of institutional investors have recently modified their holdings of the business. HRT Financial LP bought a new stake in shares of IN8bio during the 4th quarter worth $34,000. Captrust Financial Advisors bought a new position in IN8bio in the fourth quarter valued at about $43,000. Texas Capital Bank Wealth Management Services Inc bought a new position in IN8bio in the fourth quarter valued at about $56,000. Citadel Advisors LLC acquired a new position in IN8bio during the third quarter worth about $54,000. Finally, Two Sigma Investments LP acquired a new position in IN8bio during the third quarter worth about $107,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.